EBITDA: Income before interest, taxes, depreciation and amortization.
Grace Therapeutics, Inc. (GRCE) had EBITDA of $-3.01M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-1.18M |
|
-- |
|
-- |
|
$3.01M |
|
$-3.01M |
|
$0.13M |
|
$-2.88M |
|
$-2.88M |
|
$-1.18M |
|
$-1.18M |
|
$-1.18M |
|
$-1.18M |
|
$-3.01M |
|
|
EBITDA |
$-3.01M |
16.51M |
|
16.51M |
|
$-0.06 |
|
$-0.06 |
|
| Balance Sheet Financials | |
$17.38M |
|
$0.01M |
|
$49.27M |
|
$66.65M |
|
$2.15M |
|
-- |
|
$0.61M |
|
$2.76M |
|
$63.90M |
|
$14.63M |
|
$63.90M |
|
16.02M |
|
| Cash Flow Statement Financials | |
$-8.87M |
|
-- |
|
$3.71M |
|
$22.13M |
|
$16.98M |
|
$-5.16M |
|
$0.80M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.10 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-8.87M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-1.84% |
|
-8.05% |
|
-1.77% |
|
-1.84% |
|
$3.99 |
|
$-0.54 |
|
$-0.54 |
|